NEWARK, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced its participation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference in New York, New York.
Depomed’s President and CEO, Jim Schoeneck, will present a company overview on Tuesday, July 12, 2016 at 1:30 p.m. EDT.
In addition, Mr. Schoeneck will be participating in a panel discussion titled “Prescribing Opioids in an Epidemic” on Tuesday, July 12, 2016 at 12:15 p.m. EDT. Moderated by Cantor Fitzgerald’s Chiara Russo, the panel will discuss issues surrounding opioid abuse including physician prescribing habits, patient responsibility, the regulatory and reimbursement environment, and potential alternatives. Other members of the panel include:
- Charles Argoff, M.D., Professor of Neurology at Albany Medical College and Director of the Comprehensive Pain Center at Albany Medical Center, Albany, New York
- Christopher Gharibo, M.D., Associate Professor, Department of Anesthesiology, Perioperative Care, and Pain Medicine, New York University School of Medicine Langone Medical Center, New York, New York
Depomed’s presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days.
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 firstname.lastname@example.org